Scipher, Ambry partner to bring precision medicine RA test to market

Scipher Medicine announced a strategic partnership with Ambry Genetics to bring to market the former's PrismRA precision medicine test for rheumatoid arthritis (RA). Financial terms of the deal were not disclosed.

Scipher CEO Alif Saleh remarked that "in partnering with Ambry's team and their decades of experience, we are ensuring that as many patients as possible can benefit from our test by being prescribed a drug that works from day one." Aaron Elliott, chief executive at Ambry, said "we welcome the opportunity to unite our deep-rooted RNA sequencing expertise and assay validation with Scipher's impressive technology."

According to Scipher, PrismRA is a first-of-its-kind blood-based molecular signature test that accurately predicts inadequate response to TNF inhibitor therapies, the most widely prescribed targeted therapy for RA. In July, Scipher announced that results from the PrismRA clinical validation study, published in Network and Systems Medicine, met the endpoint of determining a molecular signature that accurately predicts RA patients who will fail to respond adequately to TNF inhibitors.

Multi-year agreement

Under the multi-year agreement, Ambry will use its RNA sequencing capabilities and capacity to ensure the validation, integrity and scalability of Scipher's test pipeline. The companies began working together in early 2020 to create a "robust sequencing process for PrismRA ensuring that the test can scale to provide rapid patient access," Scipher said.

To ensure you don't miss other Top Stories like these and news on key medtech industry developments, sign up for our free daily e-newsletter here.  

Did you like this article?